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Abstract
Background: Foot-and-mouth disease (FMD) is an acute, highly contagious disease that infects cloven-hoofed
animals. Vaccination is an effective means of preventing and controlling FMD. Compared to conventional
inactivated FMDV vaccines, the format of FMDV virus-like particles (VLPs) as a non-replicating particulate vaccine
candidate is a promising alternative.
Results: In this study, we have developed a co-expression system in E. coli, which drove the expression of FMDV
capsid proteins (VP0, VP1, and VP3) in tandem by a single plasmid. The co-expressed FMDV capsid proteins (VP0, VP1,
and VP3) were produced in large scale by fermentation at 10 L scale and the chromatographic purified capsid proteins
were auto-assembled as VLPs in vitro. Cattle vaccinated with a single dose of the subunit vaccine, comprising in vitro
assembled FMDV VLP and adjuvant, developed FMDV-specific antibody response (ELISA antibodies and neutralizing
antibodies) with the persistent period of 6 months. Moreover, cattle vaccinated with the subunit vaccine showed the
high protection potency with the 50 % bovine protective dose (PD50) reaching 11.75 PD50 per dose.
Conclusions: Our data strongly suggest that in vitro assembled recombinant FMDV VLPs produced from E. coli could
function as a potent FMDV vaccine candidate against FMDV Asia1 infection. Furthermore, the robust protein expression
and purification approaches described here could lead to the development of industrial level large-scale production of
E. coli-based VLPs against FMDV infections with different serotypes.
Keywords: Foot-and-mouth disease, Serotype Asia 1, Virus-like particle vaccine, Fifty percent protection dose (PD50),
Large scale production in E. coli
Highlights
1. A co-expression system in E. coli driving the expres-
sion of FMDV capsid proteins (VP0, VP1, and VP3)
in tandem by a single plasmid is constructed.
2. Large-scale chromatographic purified FMDV capsid
proteins are auto-assembled into VLPs in vitro.
3. VLP-based FMDV vaccine induces strong and
persistent humoral immunity with the period of
6 months
4. VLP-based FMDV vaccine displays strong protective
efficacy against FMDV challenge
Background
Foot-and-mouth disease (FMD) is a highly contagious
and devastating disease of cloven-hoofed animals that
causes significant economic losses worldwide [1]. FMD
is endemic in many countries including parts of Asia,
Africa, South America, and at the periphery of the
European Union [2]. The causative agent, foot-and-mouth
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disease virus (FMDV), belongs to the genus Aphthovirus
of the family Picornaviridae. The virus consists of seven
serotypes, including type A, O, C, Asia 1, and South
African Territories (SAT) 1–3 [3].
Conventional inactivated whole-virus vaccines are the
primary measure for controlling the disease in most en-
demic areas [3]. Such vaccines have played important
roles in eliminating the disease from some areas of the
world [4]. However, potential dangers still accompany
the use of whole virus vaccines because of the incom-
plete inactivation of FMDV in large-scale production
and the risk of escape of the live virus from vaccine pro-
ducing facilities [5]. Thus, a number of different types of
vaccines have been developed including synthesized pep-
tide vaccines [6], recombinant virus-vectored vaccines
[7], virus-like particles (VLPs) subunit vaccines [8–10],
and DNA vaccines [11, 12]. Among these, the VLP sub-
unit vaccine that contains all of the immunogenic sites
present on the intact virions but lacks nucleic acid
component is safe and effective. Development of VLP
vaccines has been attempted by using various expression
platforms including eukaryote and prokaryote expression
systems [8, 13]. Compared to the eukaryote expression
system, the production of recombinant proteins in the
prokaryote system, such as E. coli, is considered to be
less laborious and less expensive.
The FMDV genome contains a single large open read-
ing frame. The capsid of FMDV consists of three struc-
tural proteins VP0, VP1 and VP3, which are the cleavage
products of the P1-2A capsid precursor polypeptide
yielded from viral 3C protease digestion. During virus
maturation, capsid protein VP0 is further cleaved to
make capsid proteins VP2 and VP4. Either capsid pro-
teins VP0, VP1 and VP3 or capsid proteins VP1, VP2,
VP3 and VP4 are able to form the icosahedral capsid
particles during the different stages of virus maturation
by self-assembly [8]. In addition, two research groups
successfully produced empty icosahedral capsid particles
by expression of VP0, VP1 and VP3 capsid proteins in E.
coli by fusing these proteins with small ubiquitin-like
modifier (SUMO) tag [8, 14]. Furthermore, Guo et al. [8]
evaluated the immunogenicity of the in vitro assembled
VLPs in cattle, which is composed of capsid proteins
VP0, VP1 and VP3. However, both published methods
used 2 and 3 plasmids with different antibiotic selection
markers, respectively, to successfully co-express the
FMDV capsid protein in soluble form. However, the
multiple antibiotic selection pressure by using multiple
vectors with different antibiotic selection markers could
significantly reduce the bacterial growth and could raise
environmental and food security concerns. Moreover,
the VLP preparation protocols provided by these two pa-
pers may not be suitable for large scale production of
VLP vaccine at industrial level since neither analytical
size exclusion chromatographic approach nor sucrose
gradient ultracentrifugation approach was considered as
industrially favorable one for vaccine preparation. Fur-
thermore, the reported yield of VP0-VP1-VP3 ternary
complexes was ~5 mg/L by using two plasmids and even
less yield of ternary complexes was achieved by using
three plasmids [8, 14].
In this study, we optimized the E. coli co-expression
system by co-expressing SUMO fused full-length FMDV
capsid proteins (VP0, VP1, and VP3) in tandem driven
by a single plasmid and selected by a single antibiotic. In
our case, the co-expressed FMDV capsid proteins (VP0,
VP1, and VP3) were produced by fermentation at 10 L
scale with the protein level reaching ~50 mg/L culture
without further optimization. Furthermore, we optimized
the purification protocols by obtaining ~90 % pure FMDV
capsid proteins without size exclusion chromatographic
purification, which is not preferred at industrial level due
to the cost. The expressed full-length capsid proteins VP0,
VP1, and VP3 were in vitro assembled into VLPs, which
showed high protection potency with 11.75 PD50 per dose
when applied as subunit vaccines in cattle. Taken together,
our data provided a robust protocol, for the first time,
leading to large-scale production of potent FMDV VLP
vaccines against FMDVAsia1 infection.
Methods
Production of recombinant protein and characterization
of VLPs
The full-length FMDV VP0, VP1 and VP3 genes were
synthesized (Genewiz) and cloned into the plasmid pET-
SUMO, designated as pETSUMO-VP0, pETSUMO-VP1,
and pETSUMO-VP3, respectively. Subsequently, the
respective DNA fragments of the clones including the
ribosome binding site, the SUMO and the FMDV VP
gene, designated as RBS-SUMO-VP3, RBS-SUMO-VP1,
and RBS-SUMO-VP0, were amplified by PCR from
pETSUMO-VP3, pETSUMO-VP1 and pETSUMO-VP0,
respectively. Then these DNA fragments were cloned
into a single pET28b vector (Novagen, USA) in order.
The recombinant plasmid obtained was designated as
pET-TRI-Asia1-VP310. All the restriction enzymes were
purchased from New England Labs and the polymerases
were purchased from Qiagen.
The recombinant plasmid pET-TRI-Asia1-VP310 was
transformed into E. coli BL21 (DE3) competent cells
(Stratagene, USA) according to the manufacturer’s man-
ual. A single colony of transformant was grown in Luria-
Bertani (LB) medium containing 50 μg/ml kanamycin at
37 °C until the OD600 reached 0.8. Then isopropyl β-
D-thiogalactopyranoside (IPTG) was added to a final
concentration of 0.4 mM. The culture was incubated
for 4 h at 28 °C before subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Xiao et al. BMC Biotechnology  (2016) 16:56 Page 2 of 9
and western-blot to confirm the expression of recom-
binant protein.
Next, the fermentation was performed in 10 L bioreac-
tor (Baoxing, Shanghai, China). The media for the primary
seed, secondary seed, and fermentation of the cultures
were LB comprising tryptone 10 g/L, yeast extract 5.0 g/L,
NaCl 10 g/L, and kanamycin 50 g/L. The primary seed
culture was prepared by the transfering of 1 mL of gly-
cerol stock of recombinant E. coli strain to 50 mL of LB
medium in a 250-mL flask, which was then aerobically
incubated overnight at 37 °C. The secondary seed culture
was prepared by inoculating 2 L flasks containing 500 mL
of LB medium with 5 mL of primary seed culture and
cultivating overnight at 37 °C and 220 rpm. Flask of the
secondary seed culture were then inoculated into 5.0 L of
medium in a 10-L bioreactor and cultivating at 37 °C and
pH 7.0, in which dissolved oxygen was maintained above
20 %. The fed-batch process of recombinant protein pro-
duction in 10-L bioreactor was divided into three phases.
Phase I was an aerobic batch cultivation at 37 °C for 2 h.
Phase II was a fed-batch cultivation at 37 °C for 4 h in
which 300 g/L concentrated glucose was fed continuously
to maintain the required specific growth rate of bacteria.
In Phase III was an induction process at 37 °C for 6 h
using isopropyl-β-d-thiogalactoside (IPTG) at a final
concentration of 0.4 mM to induce the expression of
recombinant protein. The bacteria were harvested by
centrifugation and the cell pellets were re-suspended at
the buffer A (300 mM NaCl, 20 mM Tris–HCl [pH7.0]).
The cells were disrupted by homogenizer (Avestin) and
the cell supernatant was run through the His-affinity
chromatographic purification, washed by buffer B (50 mM
Tris–HCl, 0.3 M NaCl, 0.2 mM EGTA, and 40 mM imid-
azole) and eluted by using 500 mM imidazole. The SUMO
protein tag was removed by Ulp1 digestion, followed by Q
Sepharose Fast Flow anion exchange chromatographic
purification (GE Healthcare). The purified proteins
were concentrated by using Amicon centrifuge tubes
(Millipore) for small scale preparation or by using Centra-
mate TFF cassette (PALL) for large scale production. The
purified recombinant FMDV VP3, VP1 and VP0 proteins
were resuspended with 50 mM Tris–HCl, supplemented
by a series of NaCl with different concentrations. The
purified recombinant FMDV VP3, VP1 and VP0 proteins
have been almost completely re-assembled into VLPs in a
buffer of 50 mM Tris–HCl and 500 mM NaCl.
Transmission electron microscope
Purified VLPs were adsorbed onto a copper grid for 5 min
at room temperature. The grids were dried gently using
filter paper and stained with 3 % of phosphotungstic acid
(PTA) for 5 min. The excess liquid was removed with
filter, and the samples were examined under a TEM at
80 kV (FEI).
Dynamic Light Scattering (DLS) analysis of FMDV capsid
VLPs
Dynamic light scattering studies were carried out on a
DynaPro Light Scattering instrument (Wyatt Technology
Europe GmbH, Dernbach, Germany) with protein concen-
trations at A280 nm of 1.0, in buffer containing 50 mm
sodium phosphate, pH 6.5, and 5 mm DTT.
Vaccine preparation
The purified capsid protein and adjuvant ISA 206
(SEPPIC, France) was emulsified using a RW 20
homogenizer (IKA, German) under sterile conditions
at 300 rpm for 5 min, in a ratio of 46:54 (antigen:ad-
juvant) in volume. The preparations were stored at
4 °C until use.
Animals and experimental design
Vaccination and antibody monitor in cattle
Ten six-month-old cattle, sero-negative of FMDV (LPBE
antibody titers <1: 16) were randomly assigned to two
groups with 5 animals in each group. Group A and
group B were vaccinated intramuscularly once with 2 ml
of FMDV Asia1 subunit vaccine containing 200 μg
and 100 μg VLPs per cattle, respectively. Serum samples
were collected at 21, 60, 90, 120, 150 and 180 dpv,
respectively.
Fifty percent protection dose (PD50) test
Seventeen six-month-old cattle, sero-negative of FMDV
(LBPE antibody titers ≤1: 8), were divided into four
groups, and all animals were housed in an animal bio-
safety level 3 (BSL3) facility. Groups 1, 2 and 3 with 5
animals in each group were vaccinated intramuscularly
one dose subunit vaccine, 1/3 dose subunit vaccine, and
1/9 dose subunit vaccine, respectively; Group 4 with 2
animals, sham-vaccinated with PBS, was used as chal-
lenge control.
PD50 test was performed as described by the OIE to
test the potency of FMDV VLPs produced from E. coli
as a vaccine candidate. All cattle were challenged by
tongue intradermal inoculation with 10,000 bovine
infective dose 50 % (ID50) of FMDV strain Asial/JSL/
GSZY/06 per head at 28 days post vaccination (dpv).
The animals were daily examined for possible occur-
rence of lesions in the mouth and feet. Any lesion at a
site other than the inoculation site within 10 days post-
challenge was considered as a rupture of immunity and
considered as no protection.
Serum samples were collected at 0, 7, 14, 21, and 28 dpv.
The bovine PD50 content of the vaccine was calculated
based on the Reed-Muench method from each animal
protected in each group. The animal trial in this study was
approved by the Animal Care and Ethics Committee of
China National Research Center for Veterinary Medicine
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with reference number 2015062503, and conventional
animal welfare regulations and standards were taken into
account.
Serology test
The FMDV-specific antibody titers in immunized cattle
were determined by a commercial liquid-phase-block
ELISA (LPB-ELISA) kit (Lanzhou Veterinary Research
Institute, China). Virus neutralization test (VNT) was
performed according to the protocol described by the
OIE. Serum samples were inactivated at 56 °C for
30 min and subjected to a microtiter neutralization assay
on BHK-21 cells. Two-fold serially diluted sera were in-
cubated with 100 TCID50 of FMDV strain Asial/JSL/
GSZY/06 at 37 °C and 5 % CO2 for 1 h, followed by in-
fection of monolayers of BHK-21 cells in 96-well plates
for 72 h. Thereafter, the cells were examined for FMDV-
specific cytopathic effect (CPE), and neutralization titers
were calculated based on the Reed-Muench method.
Statistical analysis
All data were expressed as the mean value of five
animals ± SEM. Differences were considered statistically
significant when P < 0.05.
Results
Expression, purification, and characterization of FMDV VLPs
VP0, VP1 and VP3,the capsid proteins of FMDV, have
the ability to form empty capsids resembling the capsids
of virions and share the same antigenicity as virions. To
obtain the FMDV VLPs, the recombinant plasmid pET-
TRI-Asia1-VP310 containing the full-length of VP0, VP1
and VP3 genes in tandem was constructed. The recom-
binant expression vector was then transformed into
BL21/DE3 competent cells and protein expression was
induced by IPTG. SDS-PAGE results showed that the re-
combinant proteins of expected size were expressed
(Fig. 1). As shown in Fig. 1a, the recombinant proteins
were found in the supernatant of cells after disruption
by homogenizer (Avestin), which is about 20 % of the
total soluble proteins. Western-blot results showed that
the recombinant proteins reacted with FMDV positive
serum (Fig. 1b). The soluble fractions from bioreactor
massive production were purified by affinity chromatog-
raphy with Ni2+ resins (Novagen, USA) to capture the
His × 6-fusion proteins. After washing with washing buf-
fer (50 mM Tris–HCl, 0.3 M NaCl, 0.2 mM EGTA, and
40 mM imidazole), the target proteins were eluted by
500 mM imidazole and treated with SUMO protease
Ulp1 overnight at 4 °C to remove the SUMO tag. The
digestion products were further purified by Q Sepharose
Fast Flow anion exchange chromatographic purification.
The total purification yield is around 20 ~ 35 % (Table 1).
SDS-PAGE showed that the purity of the final
recombinant capsid protein reached ~90 % calculated by
Quantity One (Bio-Rad) (Fig. 1c). The purified recom-
binant capsid proteins (VP0, VP1 and VP3) were assem-
bled into VLPs in vitro. Dynamic light Scattering (DLS)
results showed that almost 100 % of purified capsid
proteins form uniform high molecular weight complex,
suggesting VLP formation (Fig. 2a). The assembled VLPs
were diluted in 50 mM Tris–HCl and submitted to
TEM analysis, which showed that the in vitro assembled
FMDV VLPs were rendered as hollow shapes with the
diameters of ~30 nm with 42 000 fold magnification
which consistent with the DLS results (Fig. 2b).
Immune-reactivity in cattle induced by vaccination with
VLP vaccine
Cattles were divided into two groups (groups A and B)
and submitted to vaccination with 200 μg and 100 μg
FMDV VLP per cattle, respectively. The specific anti-
FMDV antibody responses were evaluated by commer-
cial LPB-ELISA kits. As shown in Fig. 3, the specific
antibodies were detected at 21 dpv in all vaccinated ani-
mals, and the antibody levels decreased gradually there-
after (Fig. 3). The persistent periods (mean titer ≥128) of
FMDV-specific LPB antibodies in groups A and B were
6 and 3 months, respectively.
To further investigate the correlations between the
dose and the persistent period of FMDV-specific anti-
bodies, three more groups of cattle were inoculated with
one dose (200 μg), 1/3 dose, and 1/9 dose of FMDV
VLP vaccine, respectively. FMDV-special ELISA and
neutralization antibody titers were determined at 0, 7,
14, 21, and 28 dpv for each cattle. As shown in Fig. 4, all
5 animals vaccinated with 1 dose and most of the 10
cattle vaccinated with 1/3 dose and 1/9 dose FMDV
VLP vaccine developed a detectable level FMDV ELISA
antibody response at 7 dpv with the titer reaching up of
1440 (Fig. 4). Notably, the antibody titers were always
maintained at high levels for the whole experimental
period from 7dpv till 28 dpv. Consistently, FMDV-
specific neutralizing antibodies were detected only in
few serum samples at 7 dpv, which increased gradually
to reach the highest level at challenge (28 dpv) (Fig. 5).
In contrast, the antibody titers in the control group were
negative for the both LPBE and VNT groups.
PD50 test using Asia1/JSL/GSZY/06
The PD50 test was performed to assess the subunit
vaccine potency by following the bovine potency test
protocol described by the OIE to test the traditional
inactivated FMDV vaccines. When challenged with
FMDV strain Asial/JSL/GSZY/06, both the control ani-
mals exhibited typical FMD lesions on at least three feet
by 5 day post-challenge (dpc), while vaccinated animals
showed different levels of protection. All five cattle were
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considered completely protected in the 1 dose immu-
nized group, three of the four cattle were protected in
the 1/3 dose group as one cattle in this group died after
challenge with no typical lesions of FMD, and four of
the five cattle were protected in the 1/9 dose group. The
lesions in the 1/3 dose and 1/9 dose groups were
detectable by 6 dpc and the lesions were less severe
compared to control group with lesion on only one foot.
In this research, the result showed the vaccine potency
of the batch immunized with the expressed antigens
reached 11.75 PD50 per dose (Table 2). These data indi-
cated that the VLPs produced in E. coli elicited a pro-
tective immune response in cattle.
Discussion
FMD, one of the most devastating diseases of livestock,
can cause significant economic losses worldwide, and
remains the most important constraint to international
trade in live animals and animal products. FMDV is di-
vided into seven serotypes with no cross-protection con-
ferred among the serotypes, and three of which exist in
China, including serotypes O, Asia1, and A. FMDV sero-
type Asia1, an unique serotype of Asia, was first detected
Table 1 Protein yield at different purification steps
Steps Procedure Protein recovery (%)
1 Ni2+ affinity chromatography to capture
SUMO-VP proteins
70 %-80 %
2 Cleavage of SUMO tag using Ulp1 to
release the un-tagged VP proteins
60 %-70 %
3 Q Sepharose Fast Flow anion exchange
chromatography to obtain the pure VP
proteins
50 %-60 %
Total yield: 20 %-35 %
Fig. 1 SDS-PAGE and western-blot analysis of FMDV capsid proteins expressed in E. coli. a SDS-PAGE of FMDV capsid protein expression without
purification. M, protein marker; lane 1, total protein without IPTG induction; lane 2, total protein after IPTG induction; lane 3, supernatant protein
after IPTG induction; lane 4, pellet protein after IPTG induction; b Western-blot of FMDV capsid protein expression without purification. M, protein
marker; lane 1, supernatant protein after IPTG induction; lane 2, pellet protein after IPTG induction; c M, protein marker; lane 1, purified protein
complex (1ul load); lane 2, purified protein complex (10ul load); lane 3, purified protein complexes after Ulp 1 protease treatment (1ul load); lane
4, purified protein complexes after Ulp 1 protease treatment (10ul load)
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in samples collected in India in 1951 through 1952 and
Pakistan in 1954 [15]. In China, serotype Asia1 be-
came an important prevalent serotype after an
outbreak recorded in Hong Kong in 2005 [16]. FMD
vaccines are applied for prophylactic use in endemic
areas worldwide, two vaccine types including
traditional killed vaccines and synthetic peptide vac-
cines are commercially available and widely used in
China.
Although the traditional inactivated vaccine has been
proved effective, the development of a novel subunit
FMDV vaccine that is safer, more effective and more
A B
Fig. 2 Characterization of in vitro re-assembled FMDV VLPs. a DLS profile. The difference of DSL profile between two protein concentrations was
determined by using t-test in GraphPad 5.0. Differences were considered statistically significant when P < 0.05. b Images of VLPs under electron
microscope with 42000 ×magnification. The scale bar indicates 100 nm
Fig. 3 FMDV-specific immune responses in cattle measured by LPB-
ELISA. Groups of cattle (n = 5) immunized with 200ug or 100ug of
FMDV VLPs. Blood samples were collected at 21 days post-
vaccination and 2, 3,4,5 and 6 months after vaccination for the LPB-
ELISA detection. LPB-ELISA value≥ 128 (log10 2.1) indicates above
99 % protection to the viral challenge according to the
manufacture’s instruction
Fig. 4 FMDV-specific immune responses in cattle measured by
LPB-ELISA in PD50 test. Blood samples were collected at 0, 7, 14, 21,
and 28 days post-vaccination for the LPB-ELISA detection. LPB-ELISA
value≥ 128 (log10 2.1) indicates above 99 % protection to the viral
challenge according to the manufacture’s instruction. Each data points
represents the mean ± standard error of measurements for five cattle
from immunized groups and for 2 cattle from control group
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economical than traditional vaccines is essential to con-
trol FMDV spreading worldwide. Notably, FMDV is a
non-enveloped RNA virus and each FMDV capsid sub-
unit is formed by the assembly of a single copy of the
structural proteins VP0, VP1, and VP3 coded by the P1
region of the viral genome. Among them, VP0 is
digested to make capsid proteins VP2 and VP4 during
virus maturation [17]. In previous reports, the fusion
proteins of three FMDV capsid proteins, VP0, VP1 and
VP3, have been successfully expressed in E. coli as
SUMO-fusion format at ~5 mg/L level by co-
transformation of 2 or 3 plasmids with multiple anti-
biotic selections [8, 14]. No robust protocols for large
scale production and purification of FMDV VLPs were
provided. In this study, we first made a single plasmid
by constructing RBS-SUMO-VP3, RBS-SUMO-VP1 and
RBS-SUMO-VP0 genes in tandem and driven by a single
promoter with its own ribosome binding site, which led
to the co-expression of SUMO-tagged VP3, VP1 and
VP0 in E. coli, selected by only one single antibiotics.
Compared with the previous reported production of
FMDV vaccines, our protocol has the following advan-
tages. 1) The genes encoding SUMO-tagged VP3, VP1
and VP0 were constructed in tandem into a single plas-
mid and selected by a single antibiotics; 2) The SUMO-
tagged VP3, VP1 and VP0 proteins in this protocol were
expressed at soluble form with the expression level as
high as ~50 mg/L by fermentation, which was ten times
higher than the previously reported protocols [8, 14]; 3)
The addition of SUMO tags not only facilitates the
ensuing purification processes but preventing the aggre-
gation of FMDV capsid proteins; 4) A robust purification
protocol was provided to make well-assembled FMDV
VLPs with the purify reaching ~90 % without using the
Fig. 5 FMDV-specific immune responses in cattle measured by virus
neutralizing antibody test. Blood samples were collected at 0, 7, 14,
21, and 28 days post-vaccination for the virus neutralizing antibody
test. The virus neutralizing antibody was expressed by the average ti-
ters of cattle in one whole group at different time points. Each data
points represents the mean ± standard error of measurements for
five cattle from immunized groups and for 2 cattle from
control group
Table 2 Results of PD50 test. PD50 test was performed as described by the OIE. The bovine PD50 content of the vaccine was
calculated based on the Reed-Muench method from each animal protected in each group
Groups Animal
No.
Antibody titer at 28 dpv Protection Days of onset of lesion Rate of protection PD50
LPBE VN Yes - 5/5
LPBE VN Yes - 5/5 11.75
1 dose 1558 360 64 Yes -
1559 1440 64 Yes -
1584 1440 724 Yes -
1601 180 362 Yes -
1602 720 512 Yes -
1/3 dose 1534 1440 724 Yes - 3/4
1548 1440 724 No D10
1562 90 724 Deatha -
1567 720 431 Yes -
1576 180 76 Yes -
1/9 dose 29 1440 724 Yes - 4/5
77 360 54 Yes -
1136 2880 724 Yes -
1139 180 4 No D6
1580 360 512 Yes -
Control 1561 22 16 No D5 0/2
1590 45 8 No D5
a One animal in this group died after challenge, but with no typical lesions of FMD
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industrial non-preferred size exclusion chromatographic
purification or sucrose gradient ultracentrifugation steps,
which dramatically reduced the cost of vaccine produc-
tion. Moreover, the application of our in vitro assembled
FMDV VLP vaccine has successfully elicited robust high
level of VN antibodies in the tested cattle right after 28
dpv. Furthermore, high level of VN antibodies were de-
tected in all cattle of 1 dose group and 1/3 dose group,
and four out of five in 1/9 dose group (Table 1). Unex-
pected, animal No. 1548 in 1/3 dose group displaying a
high VNA titer showed no resistance to challenge. How-
ever, similar observation was also seen in previous stud-
ies of FMDV VLP subunit vaccine development [6, 8].
Although the good correlation between VNA titer and
protection to FMDV challenge was generally considered,
the disparity sometimes was reported due to variation of
individual cattle in resistance to the virus infection as
well as other immunological parameters such as cellular
immunity.
Surprisingly, in the PD50 test, the percentage protec-
tion values showed a dose independent manner since ei-
ther 1 dose, 1/3 dose or 1/9 dose FMDV VLP subunit
vaccine displays similar significant protection. This ob-
servation is also consistent with the earlier reports in the
FMDV potency tests [18, 19]. As reported by Goris et al.
[18], the largest variation in the number of protected an-
imals was observed in the lowest vaccine volume dose
group, where the entire possible range of protected ani-
mals varied widely (from 0 to 5). Nevertheless, our E.
coli-based FMDV VLP vaccines produced by large-scale
fermentation have shown the great promise in protecting
cattle from FMDV infection.
Notably, according to the World Organization for
Animal Health (OIE) manual (OIE, 2012), the FMDV
vaccine should contain at least 3 PD50 and 6 PD50
per dose for cattle when employed for routine
prophylactic vaccination and emergency vaccination,
respectively. In China, Ministry of Agriculture of
China elevated the potency criteria of all commercial
FMDV vaccines from 3 to 6 PD50 per dose in 2013
(http://www.moa.gov.cn/zwllm/tzgg/tfw/201306/t20130
613_3491208.htm). Such standard demands the devel-
opment and production of FMDV vaccines with po-
tent protection. Strikingly, our E. coli-based FMDV
VLP vaccines by fermentation achieve 11.75 PD50 per
dose in cattle. Hence, our approach in large scale
production of FMDV VLP subunit vaccine by E. coli
expression system should have direct impact in con-
trolling FMD spreading worldwide.
Conclusions
In this study, the FMDV capsid proteins VP0, VP1, and
VP3 were expressed in E. coli and assembled into VLPs
in vitro in large scale by fermentation at 10 L scale.
VLP-based FMDV vaccine induced strong and persistent
humoral immunity with the period of 6 months which
indicated this vaccine candidate could function well
against FMDV Asia1 infection.
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